# COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

> **NCT04845191** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **ImmunityBio, Inc.**

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** hAd5-S-Fusion+N-ETSD vaccine

## Key facts

- **NCT ID:** NCT04845191
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12
- **Primary completion:** 2021-12
- **Final completion:** 2021-12-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor has changed the development plans which is not for safety reasons.
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04845191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04845191, "COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04845191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*